Market Overview

Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

Share:
Related GSK
EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, Ready For Phase 1 Study By Q4
Benzinga's M&A Chatter for Thursday January 28, 2015
Is GlaxoSmithKline's 6% Dividend Sustainable? (Seeking Alpha)
Related THRX
Theravance Inc Reports Prelim Tender Offer Results
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).

Posted-In: News FDA

 

Related Articles (THRX + GSK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters